Statin use and the prevention of venous thromboembolism: A meta-analysis

International Journal of Clinical Practice

Volumn 64, Issue 10, 2010, Pages 1375-1383

  Agarwal, V ^a   Phung, O J ^b   Tongbram, V ^a,c   Bhardwaj, A ^a   Coleman, C I ^a,c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFECT; HUMAN; INCIDENCE; LUNG EMBOLISM; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 77955808780     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02439.x     Document Type: Article

References (27)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003 107 (Suppl. 1 14 8.
2. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006 4 : 1886 90.
3. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003 348 : 1435 41.
4. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 207.
5. Heart Protection Study Collaborative Group. MRCBHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
6. Kushner FG, Hand M, Smith SC et al. 2009 focused updates: ACCAHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACCAHASCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of CardiologyAmerican Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009 54 : 2205 41.
7. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulations. Arterioscler Thromb Vasc Biol 2005 25 : 287 94.
8. Grady D, Wenger NK, Herrington D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 2000 132 : 689 96.
9. Herrington DM, Vittinghoff E, Lin F et al. Statin therapy, cardiovascular events, and total mortality in the Heart and EstrogenProgestin Replacement Study (HERS). Circulation 2002 105 : 2962 7.
10. Ramcharan AS, van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJM. HMG-CoA reductiase inhibitors, other lipid-lowering medication, antiplatelet therapy, and risk of venous thrombosis. J Thromb Haemost 2009 7 : 514 20.
11. Sørenson HT, Horvath-Puho E, Søgaard KK et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009 7 : 521 8.
12. Lacut K, Le Gal G, Abalain JH, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thromb Res 2008 122 : 314 9.
13. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2008 67 : 99 109.
14. Huerta C, Johansson S, Wallander MA, Garcia Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnoses in the primary care setting in the United Kingdom. Arch Intern Med 2007 167 : 935 43.
15. Doggen CJM, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM. HMB CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004 2 : 700 1.
16. Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. J Clin Pharmacol 2002 53 : 101 5.
17. Ray JG, Mamdani M, Tsuuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001 161 : 1405 10.
18. Glynn RJ, Danielson E, Fonseca FAH et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009 360 : 1851 61.
19. Harris RP, Helfand M, Woolf SH et al. Current methods of the U.S. Preventative Services Task Force: a review of the process. Am J Prev Med 2001 20 : 21 35.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986 7 : 177 88.
21. Ray JG, Rosendaal FR. The role of dyslipidemia and statins in venous thromboembolism. Curr Control Trials Cardiovasc Med 2001 2 : 165 70.
22. Yang CC, Kao CC. Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control study. J Chin Med Assoc 2007 70 : 103 9.
23. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogenprogestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials 1998 19 : 314 35.
24. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005 365 : 1163 74.
25. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008 359 : 938 49.
26. Ageno W, Prandoni P, Romualdi E et al. The metabolic syndrome and the risk of venous thrombosis. A case control study. J Thromb Haemost 2006 4 : 1914 8.
27. Prandoni P, Ghiraduzzi A, Prins MH et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006 4 : 1891 6.